Enhanced antitumor efficacy is observed with the dual-signal T cell engager.
This approach targets KK-LC-1, leading to improved immune response against tumors.
Assessment of the dual-signal engager shows promising results in tumor models.
Further clinical evaluations are needed to confirm these findings in humans.
Abstract
Chen T, Wang Y, Chen X, et al. Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy. J Immunother Cancer 2026;14:e013246. https://doi.org/10.1136/jitc-2025-013246